Emerald Medical Applications Corp. (OTCMKTS:MRLA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On April 18, 2017, the Board of Directors of Emerald Medical
Applications Corp. (the Registrant) accepted the resignation of
Mr. David Ben Naim as Chief Financial Officer of the Registrant
and its wholly-owned Israeli subsidiary, Emerald Medical
Applications Ltd (Emerald Israel), positions he has held since
June 15, 2016. A copy of Mr. Ben Naim’s letter of resignation is
attached at Exhibit 17.8 to this Form 8-K.
In connection with the resignation of Mr. Ben Naim, the
Registrant’s Board of Directors has appointed Mr. Gadi Levin as
Chief Financial Officer of the Registrant and Emerald Israel.
Mr. Gadi Levin, age 44, Chief Financial Officer. Mr. Levin has
over 15 years of experience working with public US, Canadian and
multi-jurisdictional public companies. Mr. Levin currently serves
as Chief Financial Officer of Briacell Therapeutics Corp (OTCQB:
BCTXF, TSX-V: BRIA.V) and Adira Energy Limited (OTCMKTS:ADENF,
TSX.V: ADL.V). Previously, Mr. Levin served as Chief Financial
Officer of DarioHeath Corp (NASDAQ: DRIO), a mHealth company
operating in the field diabetes management. Mr. Levin also served
as the Vice President of Finance and Chief Financial Officer for
two Israeli investment firms specializing in private equity,
hedge funds and real estate. Mr. Levin began his CPA career at
the accounting firm, Arthur Andersen, where he worked for nine
years, specializing in U.S. listed companies involved in IPO’s
working with US GAAP and IFRS. Mr. Levin has a Bachelor of
Commerce degree in Accounting and Information Systems from the
University of the Cape Town, South Africa, and a post graduate
diploma in Accounting from the University of South Africa. He
received his Chartered Accountant designation in South Africa and
has an MBA from Bar Ilan University in Israel.
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report
on Form 8-K or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical
reference to the SEC filing that included such document.
|
Exhibit No. |
Description |
| 17.8 | Letter of Resignation dated April 18, 2017, filed herewith. |
About Emerald Medical Applications Corp. (OTCMKTS:MRLA)
Emerald Medical Applications Corp. operates through its subsidiary, Emerald Medical Applications Ltd. (Emerald), which is a digital health company. Emerald is engaged in the development, sale and service of imaging solutions utilizing its DermaCompare software that it developed for use in derma imaging and analytics. Emerald’s DermaCompare solution allows dermatologists and other medical care professionals, using a set of total body photography (TBP), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smartphones or tablets. DermaCompare imaging solution is provided as a software platform for early detection of Melanoma for classification of dermatological lesions as published by the National Institute of Health (NIH) for analysis of moles. DermaCompare imaging software solution reads and extracts data from those images and in essence turns digital camera, camera-equipped smartphones and tablets into virtual scanning devices. Emerald Medical Applications Corp. (OTCMKTS:MRLA) Recent Trading Information
Emerald Medical Applications Corp. (OTCMKTS:MRLA) closed its last trading session 00.000 at 0.155 with 12,500 shares trading hands.